Accueil > Actualité
Actualite financiere : Actualite bourse

Sanofi: UBS reiterates buy rating

(CercleFinance.com) - UBS highlights the stock's attractive valuation and strong underlying growth.
The analyst confirms his Buy rating on it, with an unchanged target price of E115.

We reiterate our Buy rating on Sanofi, seeing underlying growth and the new share buyback as key events for value creation in 2025, UBS says.

It should be remembered that Sanofi has raised its outlook for 2024, now expecting business EPS growth at CER at least in the low single-digit range, underpinned by strong business performance.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
 

societes

marches

tendances

 
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.